Jerusalem-based Oramed Pharmaceuticals has developed an innovative oral insulin capsule transforming injectable treatments into oral therapies. Oramed's CEO Nadav Kidron speaks to The Jerusalem Post about the company's technology .
Oramed CEO Nadav Kidron Speaks with Nathan Latka about Oramed, oral insulin and more. Listen to the full podcast: The Chinese Gave Him $50M For Orally Delivered Insulin Capsul Idea, Will It Take Off?
Despite an inexorable rise in the global population of type 2 diabetics, linked to changing lifestyle… Read the full article on www.thepharmaletter.com
This Tustin based Oral Insulin clinical trial in Orange County will test treatment for those with type 2 diabetes over the next 90 days. Read the full article on patch.com
For decades researchers have worked to find a way to orally administer insulin effectively to patients with diabetes. Now this game-changing treatment is one step closer to reality, with pharmaceutical company Oramed embarking on a final Phase 2b human clinical trial to prove the efficacy [...]
Nadav Kidron serves as Chief Executive Officer of Oramed Pharmaceuticals, which he co-founded in 2006. Their orally-taken insulin is game-changing technology that could revolutionize the way millions people with diabetes administer their medication. Read the full article on b2bnn.com
Millions of diabetics inject insulin daily, and millions more are on the path to injections. But Oramed Pharmaceuticals aims to change that reality, with an insulin pill. Currently in clinical trials, the oral insulin capsule could radically change how we treat diabetes, and dramatically change [...]
The “wish list”, or holy grail for diabetics who prick their finger several times a day to measure their blood sugar usually involves two things: a way to check their blood sugar without painful finger pricks, and taking a pill instead of an insulin shot. [...]
(CNN)Daily insulin shots for the management of Type 1 and Type 2 diabetes could become a thing of the past, and insulin pills could someday be another option for diabetes patients. to read the rest of the article press here
Oramed Pharmaceuticals Inc. plans a secondary listing in Tel Aviv “in the next few weeks” to take advantage of an increasing number of Israeli investors seeking new opportunities amid new measures to invigorate the stock market, CEO Nadav Kidron told Bloomberg.